| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e91879cb29d51c1dd6f6db9674957c9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17b367e96fc1b9afd2c403b58f550cf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adc048c2a637cc5389e0118ca5b5f27a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e040a90fcc5784074adcc886b526c448 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2016-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2b2a203b55f5e510b32b6dd786de030
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d629506868ad7015fe29f9e8dc9ed6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1ffc7779995df2d1aab90f5390ead2c |
| publicationDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10258633-B2 |
| titleOfInvention |
Treatment of fibrosis using FXR ligands |
| abstract |
The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions. |
| priorityDate |
2004-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |